Capsaicin patch license extension application withdrawn
21st March 2012
Astellas Pharma has withdrawn its application to the European Medicines Agency (EMA) for a license extension for Qutenza® (capsaicin 8% transdermal patch). The application was to extend the marketing authorization for Qutenza® to all adult patients with exclusion of patients with pain caused by diabetes.
The withdrawal was based on the Committee for Medicinal Products for Human Use (CHMP)'s view that the data provided would not allow the committee to conclude on a positive benefit-risk balance.
Qutenza® continues to be authorized for the treatment of peripheral neuropathic pain (PNP) in non-diabetic adults either alone or in combination with other medicinal products for pain.
- Legislation changes for controlled drugs
- Cochrane review: Buprenorphine for treating cancer pain
- New PO magnesium product for hypomagnesaemia
- Ketamine supply update
- Potential risk of error in selecting incorrect oxycodone strength
- Free access to the on-line Palliative Care Formulary renewed for NHS Scotland
- Court ruling requires NHS England to issue guidance for the prescribing and dispensing of pregabalin for neuropathic pain
- New vision for co-ordinated end of life care published
- New drug driving legislation now in force
- Save 33%: Strong opioids and the relief of cancer pain booklet